Showing results (1771-1780 of 2,593) with videos related to

Sort By:
Pageof 260
Oncotarget|June 11, 2015
Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancerFriederike Braig, Manuela März, Aneta Schieferdecker, et al.
Personality & Social Psychology Bulletin|May 24, 2021
Within-Couple Associations Between Communication and Relationship Satisfaction Over TimeMatthew D Johnson, Justin A Lavner, Marcus Mund, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II studySandra P D'Angelo, Celeste Lebbé, Laurent Mortier, et al.
Cancer|March 29, 2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanomaOmid Hamid, Robert Ilaria, Claus Garbe, et al.
Journal of Veterinary Internal Medicine|December 30, 2022
Carbohydrate pellets to assess insulin dysregulation in horsesMelody A de Laat, Tobias Warnken, Julien Delarocque, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
European Heart Journal. Imaging Methods and Practice|March 19, 2026
Evaluating biventricular diastolic function using cardiovascular magnetic resonance 4d-flow derived E/e'Leonard Grob, Jacopo Soldini, Stephanie Keser, et al.
Investigational New Drugs|September 13, 2015
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancerR van der Noll, W M Smit, A N M Wymenga, et al.
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
The Oncologist|April 22, 2026
Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLCStanislav Rosnev, Katharina Klein, Lukas Heukamp, et al.
Pageof 260